David Gandara, Co-Director of the Center for Experimental Therapeutics at the UC Davis Comprehensive Cancer Center, shared a post by Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Along this line please remember that the 838 patient PRAGMATICA Lung trial in acquired resistance comparing Pembro-Ramu to SOC (mainly Doce-Ramu) showed no superiority in OS. ‘Buyer beware’.”
Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Center, shared this post on X, adding:
“Agree David Gandara! Often times we get too excited on the ICI rechallenge part without realizing there may be NO actual benefit to the patients! This large metanalysis from our group led by Alessio Cortellini addresses that dogma to some extent ! ”
Title: PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes
Authors: Sridevi Rajeeve, Matt Wilkes, Nicole Zahradka, Lewis Tomalin, Mujahid Quidwai, Darren Pan, Nicholas J. Calafat, Martin Cusack, Adolfo Aleman, Kseniya Serebryakova, Katerina Kappes, Hayley Jackson, Sarita Agte, Santiago Thibaud, Larysa Sanchez, Shambavi Richard, Joshua Richter, Cesar Rodriguez, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Alessandro Laganà, Adriana C. Rossi, Samir Parekh.
Read the full article on Cancer Treatment Reviews.
Other articles featuring Rafeh Naqash on OncoDaily.